The number of CD56 ( bright ) natural killer cells was seven to eight times higher in both daclizumab groups than in the interferon beta and placebo group ( interferon beta and low-dose daclizumab group p = 0.002 ; interferon beta and high-dose daclizumab group p < 0.0001 ) .
